Loader

Pathways

PathWhiz ID Pathway Meta Data

PW000410

Pw000410 View Pathway
drug action

Ropivacaine Action Pathway

Homo sapiens
Ropivacaine exerts its local anaesthetic effect by blocking voltage-gated sodium channels in peripheral neurons. Ropivacaine diffuses across the neuronal plasma membrane in its uncharged base form. Once inside the cytoplasm, it is protonated and this protonated form enters and blocks the pore of the voltage-gated sodium channel from the cytoplasmic side. For this to happen, the sodium channel must first become active so that so that gating mechanism is in the open state. Therefore ropivacaine preferentially inhibits neurons that are actively firing.

PW144424

Pw144424 View Pathway
drug action

Ropivacaine Drug Metabolism Action Pathway

Homo sapiens

PW132534

Pw132534 View Pathway
metabolic

Rose bengal Drug Metabolism

Homo sapiens
Rose bengal is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Rose bengal passes through the liver and is then excreted from the body mainly through the kidney.

PW146286

Pw146286 View Pathway
drug action

Rose bengal Drug Metabolism Action Pathway

Homo sapiens

PW132558

Pw132558 View Pathway
metabolic

Rose bengal I-131 Drug Metabolism

Homo sapiens
Rose bengal I-131 is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Rose bengal I-131 passes through the liver and is then excreted from the body mainly through the kidney.

PW146131

Pw146131 View Pathway
drug action

Rose bengal I-131 Drug Metabolism Action Pathway

Homo sapiens

PW144537

Pw144537 View Pathway
drug action

Rosiglitazone Drug Metabolism Action Pathway

Homo sapiens

PW000629

Pw000629 View Pathway
drug metabolism

Rosiglitazone Metabolism Pathway

Homo sapiens
Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is extensively metabolized in the liver by the cytochrome p450 enzymes CYP2C8 and CYP2C9 to para-hydroxy rosiglitazon, ortho-hydroxy rosiglitazone and N-desmethyl rosiglitazone. N-desmethyl rosiglitazone is the major metabolite and is further metabolized to N-desmethyl-p-hydroxyrosiglitazone, N-desmethyl glucuronide rosiglitazone and N-desmethyl-O-hydroxy rosiglitazone. Both para-hydroxy rosiglitazon and ortho-hydroxy rosiglitazone are excreted as sulfated or glucuronidated metabolites.

PW144923

Pw144923 View Pathway
drug action

Rosoxacin Drug Metabolism Action Pathway

Homo sapiens

PW126059

Pw126059 View Pathway
drug action

Rosuvastatin

Homo sapiens
Statins are a class of medications that lower lipid levels and are administered to reduce illness and mortality in people who are at high risk of cardiovascular disease. Rosuvastatin is a well-tolerated orally-administered synthetic statin that reduces total cholesterol levels, low-density lipoprotein (LDL)-cholesterol, triglyceride, and very-low-density lipoprotein (VLDL)-cholesterol. It also increases levels of high-density lipoprotein (HDL)-cholesterol. It reduces cholesterol biosynthesis due to the result of a prolonged duration of HMG-CoA reductase inhibition. Reported side effects of Rosuvastatin include constipation, flatulence, dyspepsia (indigestion), abdominal pain, headache, and myalgia (muscle pain). The primary therapeutic mechanism of action of statins is the inhibition of the rate-limiting enzyme 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase in hepatocytes. HMG-CoA reductase catalyzes the conversion of HMG-CoA into mevalonic acid, a precursor for cholesterol biosynthesis. Statins bind reversibly to the active site of HMG-CoA reductase and the subsequent structural change in the enzyme effectively disables it. Due to the resulting decrease in intracellular sterol levels, the ER membrane protein INSIG no longer binds to SREBP cleavage-activating protein (SCAP) which is, itself, bound to the transcription factor sterol regulatory element-binding protein (SREBP). Freed from INSIG, SCAP escorts SREBP to the Golgi apparatus from the ER as cargo in COPII vesicles. At the Golgi membrane, two proteases, S1P and S2P, sequentially cleave the SCAP-SREBP complex, releasing the mature form of SREBP into the cytoplasm. SREBP then translocates to the nucleus where it is transported into the nucleoplasm by binding directly to importin beta in the absence of importin alpha. SREBP binds to the sterol regulatory element (SRE) present in the promoter region of genes involved in cholesterol uptake and cholesterol synthesis, including the gene encoding the low-density lipoprotein (LDL) receptor (LDL-R). As a result, LDL-R gene transcription increases which then leads to an increased synthesis of the LDL-R protein. LDL-R localizes to the endoplasmic reticulum for transport and exocytosis to the cell surface. The elevated amount of LDL-R results in more circulating free LDL cholesterol binding and subsequent internalization via endocytosis. Lysosomal degradation of the internalized LDL cholesterol elevates cellular cholesterol levels to maintain homeostasis. This drug is administered as an oral tablet.